Sign In
Buy IMTX
$10.21
+0.165 (+1.64%)
At Close: Jun 03, 2026
Stafford , Texas and Tuebingen, Germany, May 31, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and deve
Immatics Announces First Quarter 2025 Financial Results and Business Update
07:00am, Tuesday, 13'th May 2025
Houston, Texas and Tuebingen, Germany, May 13, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and develo
Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting
10:00am, Wednesday, 23'rd Apr 2025
Houston, Texas and Tuebingen, Germany, April 23, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and dev
Immatics N.V.: Trading Below Cash, But Not Without Reason
01:02pm, Friday, 28'th Mar 2025
Immatics' lead asset, IMA203, shows promising early data with a 57% ORR in heavily pretreated patients, but toxicity concerns remain. Financially, IMTX has a $540mn market cap and $628mn cash, but neg
Immatics Announces Full Year 2024 Financial Results and Business Update
07:00am, Thursday, 27'th Mar 2025
Houston, Texas and Tuebingen, Germany, March 27, 2025 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), a clinical-stage biopharmaceutical company active in the discovery and deve
New Strong Buy Stocks for February 12th
07:46am, Wednesday, 12'th Feb 2025
BOH, AUB, BHRB, IMTX and RH have been added to the Zacks Rank #1 (Strong Buy) List on February 12, 2025.
New Strong Buy Stocks for January 9th
07:59am, Thursday, 09'th Jan 2025
AFRM, ZNTL, IMTX, MRCY and DRRX have been added to the Zacks Rank #1 (Strong Buy) List on January 9, 2024.
Immatics (IMTX) Upgraded to Buy: What Does It Mean for the Stock?
01:16pm, Tuesday, 07'th Jan 2025
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Makes Immatics (IMTX) a New Buy Stock
01:00pm, Monday, 18'th Nov 2024
Immatics (IMTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates
09:10am, Monday, 18'th Nov 2024
Immatics (IMTX) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.35 per share a year ago.
Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME
07:00am, Monday, 18'th Nov 2024
The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies and TCR-based Bispecifics
Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics' TCR-T PRAME franchise to target solid cancers
Immatics (IMTX) Expected to Beat Earnings Estimates: Should You Buy?
11:05am, Tuesday, 05'th Nov 2024
Immatics (IMTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Immatics: A Promising TCR Pipeline
09:11pm, Friday, 11'th Oct 2024
Immatics is an early-stage biotech focused on cell-based immunotherapies for solid cancers. Their ACTEngine pipeline shows promise, particularly IMA203/IMA203CD8 targeting the PRAME antigen. Valuation
Immatics Announces Pricing of $150 Million Public Offering
08:50pm, Thursday, 10'th Oct 2024
H ouston, Texas and Tuebingen, Germany, October 10, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-
